HLS Therapeutics stock | Growth outlook for 2026 & price target

HLS Therapeutics

TSX:HLS

C$ 4,59

C$-0,06 (-1,29%)

4,59 C$

C$-0,06 (-1,29%)

End-of-day quote: 04/24/2026

HLS Therapeutics Stock Value

The current analyst rating for TSX:HLS is Outperform.

Outperform

HLS Therapeutics Company Info

EPS Growth 5Y

-17,31%

Market Cap

C$0,15 B

Long-Term Debt

C$0,06 B

Short Interest

0,00%

Quarterly earnings

05/14/2026

Dividend

C$0,00

Dividend Yield

0,00%

Founded

Data Unavailable

Industry

Health Care

Country

Canada

ISIN Number

CA40390B1094

Website

http://www.hlstherapeutics.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

C$7,03

53.16%

Last Update: 04/24/2026

Analysts: 3

Highest Price Target C$11,95

Average Price Target C$7,03

Lowest Price Target C$4,47

In the last five quarters, HLS Therapeutics’s Price Target has risen from C$4,36 to C$6,07 - a 39,22% increase. Two analysts predict that HLS Therapeutics’s share price will increase in the coming year, reaching C$7,03. This would represent an increase of 53,16%.

Top growth stocks in the health care sector (5Y.)

What does HLS Therapeutics do?

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets. The primary focus of the company is on the development and commercialization of its proprietary products, including Clozaril and Vascepa, and manages a Royalty Portfolio generating revenue from various pharmaceutical products. Business Segments The company operates through Pharmaceutical Sales, Royalty Management, Mar...

Business Segments

The company operates through Pharmaceutical Sales, Royalty Management, Market Expansion, and Research Collaboration and Innovation segments.

Pharmaceutical Sales

This segment’s operations are grounded in the commercialization of products like Clozaril, used for treating schizophrenia, and Vascepa, indicated for lowering triglyceride levels in adults. These specialized drugs require stringent regulations and robust supply chain management to maintain compliance and efficacy.

Royalty Management

This segment benefits from a Royalty Portfolio, where it receives royalties from global sales of certain pharmaceutical products. It allows the company to diversify its income streams beyond direct sales, thereby increasing revenue stability.

Research Collaboration and Innovation

This segment engages in partnerships with other pharmaceutical companies for research and development purposes, enabling it to innovate further and bring superior pharmaceutical products to market.

Market Expansion

This segment is in the continuous pursuit of growth via the expansion into additional therapeutic areas and the potential introduction of novel pharmaceuticals. This segment focuses on assessing market needs, competitive landscape, and regulatory compliance. Each segment is interconnected, allowing the company to leverage its resources efficiently.

Business Strategy

The company’s business strategy revolves around a multipronged approach intended to enhance market share and drive growth through innovation, strategic partnerships, and a strong focus on compliance with regulatory standards.

Geographical Markets Served

The company operates primarily in North America, focusing on both Canada and the United States for its pharmaceutical products. The company has strategically positioned itself to oversee both manufacturing rights and commercialization processes within these vital markets.

Seasonality

The pharmaceutical markets tend to remain relatively stable, allowing the company to maintain consistent revenue streams throughout the year. However, fluctuations can occur based on regulatory changes, market entrance of new competitors, or shifts in healthcare policies.

Customer

The company caters to a diverse array of customers, including healthcare professionals, hospitals, and pharmaceutical distributors. The company’s commitment to serving those who need specialized treatment fosters long-lasting relationships. The company continually seeks to expand its customer base through targeted outreach and strategic partnerships.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing tailored to its target markets. Direct sales and partnerships with healthcare providers are essential components of the distribution strategy. The utilization of digital marketing and outreach to healthcare professionals ensures that the company's products are effectively communicated to the relevant stakeholders. Additionally, participation in industry conferences and trade shows allows the company to showcase its innovations and engage with potential customers and collaborators in real time.

New support ticket

Explore

HLS Therapeutics Stock Value

HLS Therapeutics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does HLS Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

HLS Therapeutics Stock Value

HLS Therapeutics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does HLS Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.